Effect of oral triiodothyronine during amiodarone treatment for ventricular premature complexes.

Détails

ID Serval
serval:BIB_D4D1E58F73EF
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effect of oral triiodothyronine during amiodarone treatment for ventricular premature complexes.
Périodique
American Journal of Cardiology
Auteur(s)
Polikar R., Goy J.J., Schlapfer J., Lemarchand-Beraud T., Biollaz J., Magnenat P., Nicod P.
ISSN
0002-9149[print], 0002-9149[linking]
Statut éditorial
Publié
Date de publication
11/1986
Volume
58
Numéro
10
Pages
987-991
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Whether there is a link between the antiarrhythmic efficacy of amiodarone and its blocking effect on the peripheral conversion of tetraiodothyronine (T4) to triiodothyronine (T3) is uncertain. If such a link exists, oral intake of T3 during amiodarone treatment could reverse, at least partially, the antiarrhythmic efficacy of amiodarone. To assess the safety of oral intake of T3 during amiodarone treatment and gain further insight into the relation between the antiarrhythmic action of amiodarone and its metabolic effect on T4, 7 patients (aged 32 to 62 years) with multiple ventricular premature complexes (VPCs) but no underlying heart disease were studied. Antiarrhythmic treatment was indicated for symptomatic relief only. Each patient underwent a 48-hour ambulatory electrocardiographic recording, electrocardiography and thyroid function tests, including plasma T4, T3, reverse T3 (rT3), free T4, free T3 and thyroid-stimulating hormone without treatment (baseline) after 1 month of amiodarone therapy and after a second month of amiodarone therapy with increasing doses of oral T3 (up to 75 micrograms/day). Treatment with amiodarone resulted in a decrease in plasma T3 and free T3, an increase in plasma rT3, a marked diminution in the frequency of VPCs and a prolongation of the corrected QT interval (QTc). During treatment with amiodarone and T3, plasma T3 and free T3 increased and plasma T4, free T4 and rT3 levels decreased; the frequency of VPCs remained low despite shortening of the QTc to values not different from baseline. Thus, in patients with frequent VPCs and no underlying heart disease, oral intake of T3 during amiodarone treatment is safe and does not abolish the antiarrhythmic efficacy of amiodarone, despite a shortening of the QTc.(ABSTRACT TRUNCATED AT 250 WORDS)
Mots-clé
Administration, Oral, Adult, Amiodarone/therapeutic use, Cardiac Complexes, Premature/drug therapy, Electrocardiography, Female, Humans, Male, Middle Aged, Monitoring, Physiologic, Thyroid Function Tests, Thyroxine/metabolism, Triiodothyronine/administration &amp, dosage, Triiodothyronine/toxicity
Pubmed
Web of science
Création de la notice
25/01/2008 15:00
Dernière modification de la notice
20/08/2019 16:54
Données d'usage